Evolução da leucemia mielóide crônica frente à terapia com inibidores de tirosina cinase.

• Autor(a) principal: Medeiros, Leanio Eudes dos Santos
• Data de Publicação: 2014
• Tipo de documento: Trabalho de conclusão de curso
• Idioma: por
• Título da fonte: Repositório Institucional da UFPB
• Texto Completo: https://repositorio.ufpb.br/jspui/handle/123456789/607
• topic: CNPQ:: Ciências da Saúde: Famácia; Leucemia mieloíde crônica; Terapia com inibidores; Tirosina cinase

The Chronic Myeloid Leukemia (CML ) is a myeloproliferative disease by developing skilled clone of hematopoietic cells carrying Philadelfia chromoso me ( Ph ) , deriving the respective translocation between the long arms of chromosomes 9 and 22 , t( 9:22) (q34;11 ). As a result of this molecular translocatio n, there yielding a fusion BCR - ABL gene, which encodes an abnormal protein constitutively a ctive . The d evelopm ent of tyrosine kinase (ITK) BCR - ABL , princi pled for more than a decade ago , has revo lutionized the treatment of CML . The sources used for the development of scientific origin were working in the a reas of Oncology and Hematology . The information was tak en from bibliographic databases , searched from J anuary 2013 until February 2014 , investigated in the Ministry of Hea lth website of Medline/PubMed, Scielo, Scirus , and Science Direct and Ordinance Nº 1219 data, November 4 201 3/MS . The treatment of leukemia is focused on expanding the possibilities for healing and improving qu ality of life of these patients . The oral chemotherapy is a new tool for cancer treatment , and has been proven effective and is becoming more common be cause it is simple, economical, non - i nvasive and less toxic . Is also possible that the treatment is performed in the patient's home . Among the tr eatments available for leukemia , oral chemothera py is through preventive agents , as is the case of imatin ib (Glivec ® ), Dasatinib (Sprycel ® ) and Nilotinib (Tasigna ® ) that are used by chemotherapy patients with Chronic Myeloid Leukemia (LMC) . This study aims to review information about CML and treatment progress against ITK